Rosacea Treatments Market Overview

Rosacea Treatments Market Size Was Valued at USD 1.92 Billion in 2023, and is Projected to Reach USD 4.08 Billion by 2032, Growing at a CAGR of 8.75% From 2024-2032.

Rosacea is a long-lasting skin disorder that leads to facial redness, lumps, and noticeable blood vessels. Although rosacea cannot be cured, there are various treatments available to manage symptoms and enhance the look of your skin.

• Topical medications provide specific solutions. Metronidazole and azelaic acid combat both inflammation and bacteria as antibiotics. Brimonidine gel decreases the size of blood vessels to lessen redness, while ivermectin decreases inflammation and could target mites associated with rosacea. In extreme situations, doxycycline may be recommended as an oral antibiotic for controlling inflammation. Isotretinoin, a potent drug with possible adverse reactions, is only used for severe conditions that do not improve with alternative therapies and needs monitoring by a dermatologist.
• Advancements in digital health treatments are pushing forward progress in Rosacea Treatment. The management of rosacea is evolving due to the increased utilization of telemedicine and digital healthcare options, enabling remote consultations, follow-ups, and patient monitoring. This development boosts patient adherence and enhances the availability of specialized treatments, particularly in underprivileged regions. The application of digital technologies in treating rosacea offers the potential for market growth due to its more user-friendly and practical approach.

Market Dynamics and Key Factors of Rosacea Treatment

Drivers

Increasing Prevalence of Acne Diseases

According to dermatologists, the incidence rates of rosacea are very high, and it tends to be more common in fair-skinned individuals. During the assessment of rosacea in individuals, the diversity in the population should be taken into consideration. For instance, according to Howards Medical School research, the rosacea prevalence rate in all of the women, regardless of the ethnic background was 9.6 percent. At the same time, the prevalence rate in Caucasian women alone was 16% compared to the rates found in Ireland and Sweden. 

Increasing Demand for Combination Therapies

The market faces high generic penetration, due to multiple patent expiries and off-label usage of medicines. Rosacea is treated with a variety of acne treatments, including benzoyl peroxide, azelaic acid, and sulfur compounds. Even though the majority of medicines are topical or oral, there is a substantial paradigm shift going, with treatment choices progressively leaning toward combination therapy for better results.

Increasing Inclination of Drug Manufacturers Towards Patient Convenience

Prevalence of first-line treatments and convenience of patients for oral medications across the globe is considered to drive the growth of the market. Moreover, oral and topical medications are administered in combination, on a case-to-case basis, and depending upon disease severity. In such circumstances, oral medication is gradually discontinued, while topicals are used as maintenance therapy. Thereby, drug manufacturers are increasingly inclining towards patient convenience and compliant medications.

Increasing Availability of Rosacea Medication Over the Counter (OTC)

The dermatology OTC drugs market is driven by the advent of innovative drugs. The product innovations in OTC dermatology medications have increased the demand for OTC drugs. Several effective dermatology medications are now available OTC. The number of individuals suffering from rosacea is high but, only a few seek out the help of a healthcare provider to address these issues. With a growing trend among consumers to self-treat, the demand for OTC mediations is increasing.

Restraints

High Cost for The Treatment

The high cost of topical creams and medications is the main restraining factor for the development of the rosacea treatment market. In America, more than 2.16 million sought medical treatments for rosacea in 2020 which cost approximately US$ 215.71 million. Furthermore, patients and their caregivers have experienced substantial productivity loss with a total of 157.3 million USD. On the other hand, the total medical cost for rosacea treatments is a lot less than skin concerns, ulcers, and cutaneous infections

Side Effects Associated with OTC Medication

Certain rosacea treatments can cause severe allergic reactions. To avoid such a situation, it is necessary to take proper guidance before trying OTC dermatology products. The FDA has also warned against the use of OTC medications. For instance, the FDA issued an alert on the usage of certain OTC medications that can cause allergic reactions.

Opportunities

The dramatic shift in lifestyle and the changing environmental conditions due to global warming has boosted the spread of several skin disorders. Ultraviolet radiation Can exacerbate or initiate rosacea. People living in the European and American regions are mostly affected by this disease as they have a very bright skin tone. Market players can target these regions and launch new products in this region that can help reduce the complications associated with rosacea. Market players can conduct voluntary trials in this region to formulate solutions that can suit the skin condition of patients in this region. Moreover, the government in these regions is also supporting the expansion of the rosacea treatment market by providing funds for R&D activities. For instance, the USA healthcare department has funded 70 billion USD in the year 2020 to the American Academy of Dermatology and Skin diseases for rosacea and acne treatment and research and development on the medications used for disease. Moreover, the Food and Drug Administration of the USA has also funded 200 million USD for new medications used for acne.

Market Segmentation

Segmentation Analysis of Rosacea Treatment Market

Depending on the disease type, Erythematotelangiectatic {ETR} rosacea dominated the market and is expected to do the same in the forecast period. ETR rosacea is the most common type affecting both genders. Near about 80% of the total population affected by rosacea is suffering from ETR. Individuals with ETR are mainly affected by facial redness, visible surface blood vessels, and flushing. 'Erythema' is the medical term dermatologists use for redness, 'telangiectasias' are visible surface blood vessels. Patients with this type of rosacea experience a prolonged flushing period, a burning and stinging sensation after being exposed to certain environmental factors.

Depending on the treatment type, the laser therapy segment is expected to lead the rosacea treatment market in the analysis period. The heat from the light wavelength is utilized by lasers to treat the tiny, swollen red blood cells. This is a painless therapy and the results last for years. Laser therapy improves the texture of the skin and patients observe a 50-70 % reduction in their symptoms after one to three treatments. Laser therapy has fewer side effects and has long-lasting effects thus, driving the growth of the segment.

Depending on the distribution channel, the commercial drug store segment is anticipated to lead the rosacea treatment market over the projected period. There has been a significant rise in the number of patients suffering from rosacea even though, most people prefer OTC to treat the symptoms. The large-scale presence of commercial drug stores and the discounts offered by them on different medications are the essential factors expected to propel the expansion of the rosacea market.

Regional Analysis of Rosacea Treatment Market

The European region is forecasted to dominate the rosacea treatment market during the forecast period. This skin condition is the most common found in the individuals living in this region. Epidemiological studies have shown that 10% of the Swedish population have rosacea followed by the French and German population, each accounting for 2-3% prevalence. According to the European Academy of Dermatology and Venerology (EADV), near about half (47.9%) of the total European population experienced at least one dermatological condition in 2021. Atopic dermatitis (eczema) (5.34%), and acne (5.49%) were the second most and third most skin disorders respectively. Thus, the growing number of skin-related disorders is expected to drive the growth of the rosacea market in this region.

The North American region is anticipated to have the second-highest share of the rosacea treatment market over the forecast period. According to the American Academy of Dermatology, rosacea affects at least 14 million adults in the United States, or around one out of every ten people. The National Rosacea Society (NRS) estimates that there are now 16 million people living with Rosacea. Despite its relatively high prevalence, rosacea is frequently misdiagnosed or left undiagnosed. The consequence is needless suffering for many patients. The presence of prominent market players and the launch of innovative products to treat the skin conditions of patients are the essential factors expected to consolidate the development of the market in this region.

The rosacea treatment market in the Asia-Pacific region is expected to develop at a significant growth rate in the analysis period. The changing lifestyle, rise in pollution, and global warming are factors responsible for the development of rosacea in people inhabiting this region. Rapid urbanization and industrialization have triggered the factors that may cause rosacea in a certain group of individuals. The growing adoption of cosmetics and the increasing smoker's population may drive the incidence rates of rosacea thus, strengthening the growth of the market in this region.  

Players Covered in Rosacea Treatments market are :

• Nestle Skin (US)
• GlaxoSmithKline plc (UK)
• Viatris Inc. (US)
• Body Glide (US)
• Sun Pharma (India)
• Perrigo (Ireland)
• Bayer (Germany)
• Pfizer (US)
• Teva (Israel)
• Allergan (Ireland)
• Bausch Health (Canada)
• Almirall (Spain)

Recent Industry Developments in Rosacea Treatment Market

• 03 July 2024 GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their respective mRNA development activities.  Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac currently have vaccine candidates for seasonal influenza and COVID-19 in phase II and avian influenza in phase I clinical development. All candidates are based on CureVac’s proprietary second-generation mRNA backbone. Data generated to date for these candidate vaccines are promising and demonstrate their potential to be best-in-class new vaccines.

• June 21, 2024, Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name “Voltapraz”. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Disease Type
 3.2 By Treatment Type
 3.3 By Distribution Channel

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Rosacea Treatment Market by Disease Type
 5.1 Rosacea Treatment Market Overview Snapshot and Growth Engine
 5.2 Rosacea Treatment Market Overview
 5.3 Erythematotelangiectatic
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Erythematotelangiectatic: Grographic Segmentation
 5.4 Papulopustular
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Papulopustular: Grographic Segmentation
 5.5 Phymatous
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Phymatous: Grographic Segmentation
 5.6 Ocular
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Ocular: Grographic Segmentation

Chapter 6: Rosacea Treatment Market by Treatment Type
 6.1 Rosacea Treatment Market Overview Snapshot and Growth Engine
 6.2 Rosacea Treatment Market Overview
 6.3 Laser Treatment
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Laser Treatment: Grographic Segmentation
 6.4 Electrocautery
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Electrocautery: Grographic Segmentation
 6.5 Surgery
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Surgery: Grographic Segmentation
 6.6 Others
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Others: Grographic Segmentation

Chapter 7: Rosacea Treatment Market by Distribution Channel
 7.1 Rosacea Treatment Market Overview Snapshot and Growth Engine
 7.2 Rosacea Treatment Market Overview
 7.3 Commercial Drug Stores
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Commercial Drug Stores: Grographic Segmentation
 7.4 Hospital Stores
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Hospital Stores: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Rosacea Treatment Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Rosacea Treatment Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Rosacea Treatment Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 NESTLE SKIN
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 GLAXOSMITHKLINE PLC
 8.4 VIATRIS INC.
 8.5 BODY GLIDE
 8.6 SUN PHARMA
 8.7 PERRIGO
 8.8 BAYER
 8.9 PFIZER
 8.10 TEVA
 8.11 ALLERGAN
 8.12 BAUSCH HEALTH
 8.13 ALMIRALL
 8.14 OTHER MAJOR PLAYERS

Chapter 9: Global Rosacea Treatment Market Analysis, Insights and Forecast, 2017-2032
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Disease Type
  9.2.1 Erythematotelangiectatic
  9.2.2 Papulopustular
  9.2.3 Phymatous
  9.2.4 Ocular
 9.3 Historic and Forecasted Market Size By Treatment Type
  9.3.1 Laser Treatment
  9.3.2 Electrocautery
  9.3.3 Surgery
  9.3.4 Others
 9.4 Historic and Forecasted Market Size By Distribution Channel
  9.4.1 Commercial Drug Stores
  9.4.2 Hospital Stores

Chapter 10: North America Rosacea Treatment Market Analysis, Insights and Forecast, 2017-2032
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Disease Type
  10.4.1 Erythematotelangiectatic
  10.4.2 Papulopustular
  10.4.3 Phymatous
  10.4.4 Ocular
 10.5 Historic and Forecasted Market Size By Treatment Type
  10.5.1 Laser Treatment
  10.5.2 Electrocautery
  10.5.3 Surgery
  10.5.4 Others
 10.6 Historic and Forecasted Market Size By Distribution Channel
  10.6.1 Commercial Drug Stores
  10.6.2 Hospital Stores
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe Rosacea Treatment Market Analysis, Insights and Forecast, 2017-2032
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Disease Type
  11.4.1 Erythematotelangiectatic
  11.4.2 Papulopustular
  11.4.3 Phymatous
  11.4.4 Ocular
 11.5 Historic and Forecasted Market Size By Treatment Type
  11.5.1 Laser Treatment
  11.5.2 Electrocautery
  11.5.3 Surgery
  11.5.4 Others
 11.6 Historic and Forecasted Market Size By Distribution Channel
  11.6.1 Commercial Drug Stores
  11.6.2 Hospital Stores
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific Rosacea Treatment Market Analysis, Insights and Forecast, 2017-2032
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Disease Type
  12.4.1 Erythematotelangiectatic
  12.4.2 Papulopustular
  12.4.3 Phymatous
  12.4.4 Ocular
 12.5 Historic and Forecasted Market Size By Treatment Type
  12.5.1 Laser Treatment
  12.5.2 Electrocautery
  12.5.3 Surgery
  12.5.4 Others
 12.6 Historic and Forecasted Market Size By Distribution Channel
  12.6.1 Commercial Drug Stores
  12.6.2 Hospital Stores
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa Rosacea Treatment Market Analysis, Insights and Forecast, 2017-2032
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Disease Type
  13.4.1 Erythematotelangiectatic
  13.4.2 Papulopustular
  13.4.3 Phymatous
  13.4.4 Ocular
 13.5 Historic and Forecasted Market Size By Treatment Type
  13.5.1 Laser Treatment
  13.5.2 Electrocautery
  13.5.3 Surgery
  13.5.4 Others
 13.6 Historic and Forecasted Market Size By Distribution Channel
  13.6.1 Commercial Drug Stores
  13.6.2 Hospital Stores
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America Rosacea Treatment Market Analysis, Insights and Forecast, 2017-2032
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Disease Type
  14.4.1 Erythematotelangiectatic
  14.4.2 Papulopustular
  14.4.3 Phymatous
  14.4.4 Ocular
 14.5 Historic and Forecasted Market Size By Treatment Type
  14.5.1 Laser Treatment
  14.5.2 Electrocautery
  14.5.3 Surgery
  14.5.4 Others
 14.6 Historic and Forecasted Market Size By Distribution Channel
  14.6.1 Commercial Drug Stores
  14.6.2 Hospital Stores
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ROSACEA TREATMENT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ROSACEA TREATMENT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ROSACEA TREATMENT MARKET COMPETITIVE RIVALRY
TABLE 005. ROSACEA TREATMENT MARKET THREAT OF NEW ENTRANTS
TABLE 006. ROSACEA TREATMENT MARKET THREAT OF SUBSTITUTES
TABLE 007. ROSACEA TREATMENT MARKET BY DISEASE TYPE
TABLE 008. ERYTHEMATOTELANGIECTATIC MARKET OVERVIEW (2016-2028)
TABLE 009. PAPULOPUSTULAR MARKET OVERVIEW (2016-2028)
TABLE 010. PHYMATOUS MARKET OVERVIEW (2016-2028)
TABLE 011. OCULAR MARKET OVERVIEW (2016-2028)
TABLE 012. ROSACEA TREATMENT MARKET BY TREATMENT TYPE
TABLE 013. LASER TREATMENT MARKET OVERVIEW (2016-2028)
TABLE 014. ELECTROCAUTERY MARKET OVERVIEW (2016-2028)
TABLE 015. SURGERY MARKET OVERVIEW (2016-2028)
TABLE 016. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 017. ROSACEA TREATMENT MARKET BY DISTRIBUTION CHANNEL
TABLE 018. COMMERCIAL DRUG STORES MARKET OVERVIEW (2016-2028)
TABLE 019. HOSPITAL STORES MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA ROSACEA TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 021. NORTH AMERICA ROSACEA TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 022. NORTH AMERICA ROSACEA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 023. N ROSACEA TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE ROSACEA TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 025. EUROPE ROSACEA TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 026. EUROPE ROSACEA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 027. ROSACEA TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 028. ASIA PACIFIC ROSACEA TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 029. ASIA PACIFIC ROSACEA TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 030. ASIA PACIFIC ROSACEA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 031. ROSACEA TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 032. MIDDLE EAST & AFRICA ROSACEA TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 033. MIDDLE EAST & AFRICA ROSACEA TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA ROSACEA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 035. ROSACEA TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 036. SOUTH AMERICA ROSACEA TREATMENT MARKET, BY DISEASE TYPE (2016-2028)
TABLE 037. SOUTH AMERICA ROSACEA TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 038. SOUTH AMERICA ROSACEA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 039. ROSACEA TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 040. NESTLE SKIN: SNAPSHOT
TABLE 041. NESTLE SKIN: BUSINESS PERFORMANCE
TABLE 042. NESTLE SKIN: PRODUCT PORTFOLIO
TABLE 043. NESTLE SKIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 044. GLAXOSMITHKLINE PLC: BUSINESS PERFORMANCE
TABLE 045. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 046. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. VIATRIS INC.: SNAPSHOT
TABLE 047. VIATRIS INC.: BUSINESS PERFORMANCE
TABLE 048. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 049. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. BODY GLIDE: SNAPSHOT
TABLE 050. BODY GLIDE: BUSINESS PERFORMANCE
TABLE 051. BODY GLIDE: PRODUCT PORTFOLIO
TABLE 052. BODY GLIDE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. SUN PHARMA: SNAPSHOT
TABLE 053. SUN PHARMA: BUSINESS PERFORMANCE
TABLE 054. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 055. SUN PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. PERRIGO: SNAPSHOT
TABLE 056. PERRIGO: BUSINESS PERFORMANCE
TABLE 057. PERRIGO: PRODUCT PORTFOLIO
TABLE 058. PERRIGO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. BAYER: SNAPSHOT
TABLE 059. BAYER: BUSINESS PERFORMANCE
TABLE 060. BAYER: PRODUCT PORTFOLIO
TABLE 061. BAYER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. PFIZER: SNAPSHOT
TABLE 062. PFIZER: BUSINESS PERFORMANCE
TABLE 063. PFIZER: PRODUCT PORTFOLIO
TABLE 064. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. TEVA: SNAPSHOT
TABLE 065. TEVA: BUSINESS PERFORMANCE
TABLE 066. TEVA: PRODUCT PORTFOLIO
TABLE 067. TEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. ALLERGAN: SNAPSHOT
TABLE 068. ALLERGAN: BUSINESS PERFORMANCE
TABLE 069. ALLERGAN: PRODUCT PORTFOLIO
TABLE 070. ALLERGAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. BAUSCH HEALTH: SNAPSHOT
TABLE 071. BAUSCH HEALTH: BUSINESS PERFORMANCE
TABLE 072. BAUSCH HEALTH: PRODUCT PORTFOLIO
TABLE 073. BAUSCH HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. ALMIRALL: SNAPSHOT
TABLE 074. ALMIRALL: BUSINESS PERFORMANCE
TABLE 075. ALMIRALL: PRODUCT PORTFOLIO
TABLE 076. ALMIRALL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 077. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 078. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 079. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ROSACEA TREATMENT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ROSACEA TREATMENT MARKET OVERVIEW BY DISEASE TYPE
FIGURE 012. ERYTHEMATOTELANGIECTATIC MARKET OVERVIEW (2016-2028)
FIGURE 013. PAPULOPUSTULAR MARKET OVERVIEW (2016-2028)
FIGURE 014. PHYMATOUS MARKET OVERVIEW (2016-2028)
FIGURE 015. OCULAR MARKET OVERVIEW (2016-2028)
FIGURE 016. ROSACEA TREATMENT MARKET OVERVIEW BY TREATMENT TYPE
FIGURE 017. LASER TREATMENT MARKET OVERVIEW (2016-2028)
FIGURE 018. ELECTROCAUTERY MARKET OVERVIEW (2016-2028)
FIGURE 019. SURGERY MARKET OVERVIEW (2016-2028)
FIGURE 020. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 021. ROSACEA TREATMENT MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 022. COMMERCIAL DRUG STORES MARKET OVERVIEW (2016-2028)
FIGURE 023. HOSPITAL STORES MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA ROSACEA TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE ROSACEA TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC ROSACEA TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA ROSACEA TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA ROSACEA TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)